Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Duygu Sezen; Vivek Verma; Kewen He; Chike O. Abana; Hampartsaum Barsoumian; Matthew S. Ning; Chad Tang; Pervin Hurmuz; Nahum Puebla-Osorio; Dawei Chen; Irwin Tendler; Nathan Comeaux; Quynh Nhu Nguyen; Joe Y. Chang; James W. Welsh

doi:10.1016/j.semradonc.2021.02.005

Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Duygu Sezen, Vivek Verma, Kewen He, Chike O. Abana, Hampartsaum Barsoumian, Matthew S. Ning, Chad Tang, Pervin Hurmuz, Nahum Puebla-Osorio, Dawei Chen, Irwin Tendler, Nathan Comeaux, Quynh Nhu Nguyen, Joe Y. Chang, James W. Welsh

Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic—previously thought to be incurable—disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.

Original language	English (US)
Pages (from-to)	217-226
Number of pages	10
Journal	Seminars in radiation oncology
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.semradonc.2021.02.005
State	Published - Jul 2021

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/j.semradonc.2021.02.005

Cite this

Sezen, D., Verma, V., He, K., Abana, C. O., Barsoumian, H., Ning, M. S., Tang, C., Hurmuz, P., Puebla-Osorio, N., Chen, D., Tendler, I., Comeaux, N., Nguyen, Q. N., Chang, J. Y., & Welsh, J. W. (2021). Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Seminars in radiation oncology, 31(3), 217-226. https://doi.org/10.1016/j.semradonc.2021.02.005

Sezen, D, Verma, V, He, K, Abana, CO, Barsoumian, H , Ning, MS , Tang, C, Hurmuz, P, Puebla-Osorio, N, Chen, D, Tendler, I, Comeaux, N, Nguyen, QN , Chang, JY & Welsh, JW 2021, 'Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease', Seminars in radiation oncology, vol. 31, no. 3, pp. 217-226. https://doi.org/10.1016/j.semradonc.2021.02.005

@article{d50668c1784d4a65b3d4437f28bd7635,

title = "Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease",

abstract = "Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic—previously thought to be incurable—disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.",

author = "Duygu Sezen and Vivek Verma and Kewen He and Abana, {Chike O.} and Hampartsaum Barsoumian and Ning, {Matthew S.} and Chad Tang and Pervin Hurmuz and Nahum Puebla-Osorio and Dawei Chen and Irwin Tendler and Nathan Comeaux and Nguyen, {Quynh Nhu} and Chang, {Joe Y.} and Welsh, {James W.}",

note = "Funding Information: Supported in part by Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health, to The University of Texas MD Anderson Cancer Center. Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jul,

doi = "10.1016/j.semradonc.2021.02.005",

language = "English (US)",

volume = "31",

pages = "217--226",

journal = "Seminars in radiation oncology",

issn = "1053-4296",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

AU - Sezen, Duygu

AU - Verma, Vivek

AU - He, Kewen

AU - Abana, Chike O.

AU - Barsoumian, Hampartsaum

AU - Ning, Matthew S.

AU - Tang, Chad

AU - Hurmuz, Pervin

AU - Puebla-Osorio, Nahum

AU - Chen, Dawei

AU - Tendler, Irwin

AU - Comeaux, Nathan

AU - Nguyen, Quynh Nhu

AU - Chang, Joe Y.

AU - Welsh, James W.

N1 - Funding Information: Supported in part by Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute, National Institutes of Health, to The University of Texas MD Anderson Cancer Center. Publisher Copyright: © 2021

PY - 2021/7

Y1 - 2021/7

N2 - Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic—previously thought to be incurable—disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.

AB - Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic—previously thought to be incurable—disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85102076098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102076098&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2021.02.005

DO - 10.1016/j.semradonc.2021.02.005

M3 - Review article

C2 - 34090648

AN - SCOPUS:85102076098

SN - 1053-4296

VL - 31

SP - 217

EP - 226

JO - Seminars in radiation oncology

JF - Seminars in radiation oncology

IS - 3

ER -

Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this